The Vox Markets Podcast

Watch on YouTube After this morning's trading update, CEO Martin Gouldstone of Oncimmune - a leading life sciences firm providing autoantibody profiling services to the Biopharma industry – takes me through the company's current demand picture, pipeline and August FY25 guidance.  

Watch on YouTube In this week’s Exchange, accomplished UK fund manager Richard Staveley of Harwood Capital, who runs the Rockwood Strategic investment trust, takes me through his latest thoughts on the following: 00:00 Secret sauce behind Rockwood’s success. 06:40 Capita 13:35 Filtronic & how to value the stock 19:05 Funding Circle 24:00 Vanquis Banking 32:55 Argentex 38:50 RM 43:00 Van Elle 47:25 Flowtech Fluidpower 52:25 James Fisher 56:30 STV Group 1:0:55 Kooth 1:06:25 Pennant International 1:10:35 Favourite stock idea for 2025 & portfolio management

Watch on YouTube More drilling news from Rome Resources, this time at Kalayi. Paul Barrett joins us to explain the significance of the latest results, what it all means, and what will happen next

Exciting times for the company as we sit down with Mo to discuss a record-breaking FY24, the game-changing acquisition of two clinical research units from CRS, and the strategic vision driving future growth. Mo shares insights on the synergies behind the CRS deal, the growing order book, and the evolving £40m pipeline of opportunities. Plus, we explore what’s next for the company’s M&A strategy. Don’t miss this deep dive into a company on the rise!”

Watch on YouTube Following today’s positive FY'24 trading update, CEO Jonathan Hunter and CFO Neil Pritchard of Eleco #ELCO kindly take me through the: 00:00 Current demand picture & recent client wins for Eleco’s Buildtech software. 05:20 Financial highlights 10:10 Strategic rationale & integration of Jan’s €8.4m acquisition of PMI Software 13:50 Outlook for 2025 and beyond. Disclosure: I own shares in Eleco, who is also a Vox Markets client

Watch on YouTube Following today’s resilient FY'24 trading update, CEO Shanker Patel & CFO Stuart Kilpatrick of Lords Group Trading - a specialist UK builders merchant & heating/plumbing products distributor – take me through the : State of the UK building products market & timing of recovery. Financial highlights & outlook for 2025. Why investors should remain optimistic.

Watch on YouTube In an exclusive interview, hVIVO CEO Mo Khan discusses the company’s latest milestone—a world-first pivotal Phase 3 human challenge trial for a whooping cough (pertussis) vaccine candidate. Mo delves into why ILiAD is leading this groundbreaking initiative, the trial’s key objectives, and its significance for hVIVO’s expanding portfolio. He also provides insight into the increasing global burden of pertussis and hVIVO’s readiness to conduct bacterial challenge trials at its state-of-the-art Canary Wharf facility.

Watch on YouTube In this week’s smallcap investing show, UK analyst & stock markets commentator Paul Scott & I discussed our latest thoughts on the following: 00:00 Are animal spirits returning to the equity markets? 02:30 Which sectors might benefit from UK government deregulation? 04:50 Serica Energy  09:20 Watkin Jones 10:10 abrdn 13:25 Capital (Drilling) Ltd 16:45 Beeks Financial 20:15 Cordel Group 25:50 Windar Photonics 29:25 Colefax 31:50 Zotefoams 33:25 Spectra Systems 35:35 James Latham 37:25 Epwin Group 39:10 Card Factory 40:50 JD Sports 44:00 Creo Medical 48:55 Feedback Medical 51:35 LBG Media 55:20 System1 58:05 1Spatial Due to a diary clash, the next episode is in 2 weeks time (Friday 7th Feb) Finally, if anyone or any company would like to sponsor this Smallcap Investing series (re naming rights), then please feel free to contact me here or via my email paulhill@pmhcapital.com. #SQZ #WJG #ABDN #CAPD #BKS #CRDL #WPHO #CFX #ZTF #SPSY #LTHM #EPWN #CARD #JD. #CREO #CREO #FDBK #LBG #SYS1 #SPA

Watch on YouTube Rome Resources has released assay results from two holes drilled at its Mont Agoma tin project in the Democratic Republic of Congo. The results support the company's geological interpretation of Mont Agoma, and the grades look world class. Chief executive Paul Barrett joints us to explain.

Watch on YouTube hVIVO has secured a £2.7 million contract for its hLAB division to serve as the sole virology lab for a global Phase 2 influenza drug study involving 5,000 participants. This milestone marks hVIVO's largest standalone lab services contract, leveraging its expanded Canary Wharf facility.